DTaP vaccine


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to DTaP vaccine: Hib vaccine

DTaP vaccine

A preparation of diphtheria and tetanus toxoids and acellular pertussis proteins. It is used to immunize children against all three infections or adults at high risk of complications of infection with pertussis.
See also: vaccine
References in periodicals archive ?
Food and Drug Administration, Abbott Laboratories will market and distribute the DTaP vaccine and the combination vaccines to private physicians and managed care markets in the United States for immunization of infants and children.
And in 1996, it was the first company to license a DTaP vaccine for use in infants (Tripedia(R)(e) vaccine).
licensed whole-cell DTP vaccine, a chemically detoxified DTaP vaccine, a diphtheria and tetanus vaccine alone, or Pertugen.
The product registration application for the DTaP vaccine was filed in 1995 by Statens Seruminstitut with the regulatory authorities in Sweden after successful completion of an efficacy study in Goteborg, Sweden.
In this project to date, over 10,000 infants and children have received the Company's DTaP vaccine with no vaccine associated serious adverse reactions reported and the Company expects that total enrollment will exceed 43,000.
The Company is seeking regulatory approval of its DTaP vaccine for all primary and booster doses for infants and children.
The increase in the operating loss for the quarter and six months ended June 30, 1995 as compared to last year is primarily clinical testing and related expenses, professional fees and increased labor costs as the Company adds personnel and prepares to file for regulatory approval of its DTaP vaccine.
This is like deja vu for those of us who watched the FDA fail to properly regulate the drug industry after the less reactive DTaP vaccine was licensed for babies in 1996.
A total of 14,832 infants received all three immunizations at two, four and six months with one of four vaccines: a genetically engineered DTaP (acellular pertussis combined with diphtheria and tetanus toxoids) vaccine formulation from Chiron Biocine; a chemically detoxified DTaP vaccine formulation from SmithKline Beecham; a DTP (whole-cell pertussis combined with diphtheria and pertussis) vaccine formulation from Connaught Laboratories Incorporated; or a placebo of DT (diphtheria and tetanus toxoids) from Chiron Biocine.
In addition, the use of Boostrix induced anti-pertussis antibody levels which were non inferior to those observed in infants following a primary immunization series with a DTaP vaccine (Infanrix(R)) [Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed] in whom efficacy against pertussis disease was demonstrated in a previous study.
The Company believes these results can only assist the Company in obtaining approval and acceptance for its DTaP vaccine.
In addition, the use of Boostrix induced anti-pertussis antibody levels, which were statistically higher than those observed in infants following primary immunization with a DTaP vaccine (Infanrix(R)) [Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed] in whom efficacy against pertussis disease was demonstrated in a previous study.